News
-
-
PRESS RELEASE
Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results
Applied DNA Sciences, Inc. announces third quarter financial results for June 30, 2024, including operational highlights and future plans. Conference call/webcast today at 4:30 PM ET. View Form 10-Q at https://investors.adnas.com/sec-filings/ -
-
PRESS RELEASE
CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
Applied DNA Sciences, Inc. presents Linea IVT platform for enhanced mRNA production at 4th Annual mRNA-based Therapeutics Summit. Solution reduces dsRNA contamination, streamlines workflows, and boosts efficiency -
-
PRESS RELEASE
U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract
Applied DNA Sciences announces $1.04 million contract with U.S. Defense Logistics Agency for counterfeit mitigation and product verification programs specific to FSC 5962 microcircuits. Continues support since 2014 -
-
PRESS RELEASE
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
Applied DNA and Alphazyme announce successful conclusion of Linea RNAP manufacturing scale-up agreement, resulting in over 70% cost reduction and sufficient quantity for near-term demand. Partnership enhances Linea IVT platform profitability -
-
PRESS RELEASE
Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing
Applied DNA partners with GenXys Health Care Systems to enhance precision prescribing decisions through TR8 PGx test. The partnership aims to improve patient outcomes and reduce healthcare costs